A French pharmaceutical giant is acquiring a biotech and its rare immunology disease treatment which is already approved in ...

Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 ...

The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

Paris: Sanofi and Blueprint Medicines Corporation, a US-based, publicly traded biopharmaceutical company specializing in ...

As part of a strategy to strengthen its immunology segment through acquisitions, Sanofi has agreed to buy US-based Blueprint ...

Sanofi is set to acquire Blueprint Medicines, a US-based biopharmaceutical company specialising in systemic mastocytosis.

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...

Sanofi (SNY) has its hands full—in the best way possible—after announcing its $9.5 billion acquisition of Blueprint Medicines. This marks the French pharma giant’s fourth major strategic acquisition ...